{"id":18270,"date":"2025-06-12T08:09:01","date_gmt":"2025-06-12T06:09:01","guid":{"rendered":"https:\/\/tech4future.info\/?p=18270"},"modified":"2025-06-12T09:27:50","modified_gmt":"2025-06-12T07:27:50","slug":"glue-degraders-proxygen","status":"publish","type":"post","link":"https:\/\/tech4future.info\/en\/glue-degraders-proxygen\/","title":{"rendered":"Glue Degraders: A New Class of Drugs Poised to Overcome the Limitations of Traditional Pharmacology"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Within the field of molecular pharmacology, glue degraders are emerging as one of the most promising innovations for overcoming the inherent constraints of conventional therapies. These small molecules are designed to induce the selective degradation of pathogenic proteins by harnessing the body\u2019s endogenous cellular\u2011disposal mechanisms &#8211; a strategy that could potentially expand the scope of druggable targets to as much as 90\u202f% of the human proteome.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Unlike classical inhibitors, which merely block the functional activity of the target protein, glue degraders promote its elimination by facilitating the formation of a complex between the target protein and an <strong><a href=\"https:\/\/en.wikipedia.org\/wiki\/Ubiquitin_ligase\" target=\"_blank\" rel=\"noreferrer noopener\">E3 ubiquitin ligase<\/a><\/strong>. This interaction tags the protein for destruction by the proteasome, effectively removing it from the cellular environment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Proxygen, a biotechnology company, has chosen to focus its efforts precisely on this domain. It has developed a proprietary platform for the systematic discovery of glue degraders and is now on the cusp of initiating clinical trials with its first candidate &#8211; a compound aimed at a target that has, until now, been deemed undruggable. The therapeutic potential is broad and spans multiple areas, from oncology to neurodegenerative diseases, pointing to a possible paradigm shift in pharmaceutical discovery.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We had the opportunity to speak with its CEO, <strong>Bernd Boidol<\/strong>, to gain deeper insight into how research in this field is evolving.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading has-text-color has-link-color wp-elements-1\" id=\"h-takeaways\" style=\"color:#73cc49\">Takeaways<\/h2>\n\n\n\n<div class=\"wp-block-uagb-icon-list uagb-block-784d3ea0\"><div class=\"uagb-icon-list__wrap\">\n<div class=\"wp-block-uagb-icon-list-child uagb-block-cc5690de\"><span class=\"uagb-icon-list__source-wrap\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M256 0C114.6 0 0 114.6 0 256c0 141.4 114.6 256 256 256s256-114.6 256-256C512 114.6 397.4 0 256 0zM406.6 278.6l-103.1 103.1c-12.5 12.5-32.75 12.5-45.25 0s-12.5-32.75 0-45.25L306.8 288H128C110.3 288 96 273.7 96 256s14.31-32 32-32h178.8l-49.38-49.38c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0l103.1 103.1C414.6 241.3 416 251.1 416 256C416 260.9 414.6 270.7 406.6 278.6z\"><\/path><\/svg><\/span><span class=\"uagb-icon-list__label\"><strong>Glue degraders broaden the scope of druggability <\/strong>within the human proteome, enabling therapeutic strategies against disease\u2011related proteins that have so far proven inaccessible to conventional approaches.<\/span><\/div>\n\n\n\n<div class=\"wp-block-uagb-icon-list-child uagb-block-27c1012e\"><span class=\"uagb-icon-list__source-wrap\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M256 0C114.6 0 0 114.6 0 256c0 141.4 114.6 256 256 256s256-114.6 256-256C512 114.6 397.4 0 256 0zM406.6 278.6l-103.1 103.1c-12.5 12.5-32.75 12.5-45.25 0s-12.5-32.75 0-45.25L306.8 288H128C110.3 288 96 273.7 96 256s14.31-32 32-32h178.8l-49.38-49.38c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0l103.1 103.1C414.6 241.3 416 251.1 416 256C416 260.9 414.6 270.7 406.6 278.6z\"><\/path><\/svg><\/span><span class=\"uagb-icon-list__label\">Their catalytic and selective mechanism of protein degradation <strong>allows for therapeutic efficacy at lower doses<\/strong>, reducing side effects and extending the pharmacological effect.<\/span><\/div>\n\n\n\n<div class=\"wp-block-uagb-icon-list-child uagb-block-627bb974\"><span class=\"uagb-icon-list__source-wrap\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M256 0C114.6 0 0 114.6 0 256c0 141.4 114.6 256 256 256s256-114.6 256-256C512 114.6 397.4 0 256 0zM406.6 278.6l-103.1 103.1c-12.5 12.5-32.75 12.5-45.25 0s-12.5-32.75 0-45.25L306.8 288H128C110.3 288 96 273.7 96 256s14.31-32 32-32h178.8l-49.38-49.38c-12.5-12.5-12.5-32.75 0-45.25s32.75-12.5 45.25 0l103.1 103.1C414.6 241.3 416 251.1 416 256C416 260.9 414.6 270.7 406.6 278.6z\"><\/path><\/svg><\/span><span class=\"uagb-icon-list__label\">Proxygen is advancing a pipeline of glue degraders discovered through a systematic approach, with its lead candidate in <strong>late\u2011stage preclinical development<\/strong> and a scalable platform ready for future industrial partnerships.<\/span><\/div>\n<\/div><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-druggability-and-undruggable-proteins-a-defining-challenge-in-modern-pharmacology\"><strong>Druggability and \u201cUndruggable\u201d Proteins: A Defining Challenge in Modern Pharmacology<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Over the past decade, a pivotal concept has taken root in pharmacological research: <strong>druggability<\/strong>. The term refers to the feasibility of targeting a specific protein with a drug. Typically, these are abnormal proteins arising from genetic mutations, which play a central role in the onset and progression of various diseases. If a protein is deemed <em>druggable<\/em>, it means it can be bound and neutralised by a therapeutic agent &#8211; for instance, a monoclonal antibody. This strategy is already in use for treating a range of cancers, as well as autoimmune diseases such as Crohn\u2019s disease, rheumatoid arthritis, and systemic lupus erythematosus, all of which involve malfunctioning proteins.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In the field of drug discovery &#8211; the scientific process through which new therapeutic compounds are identified by their <strong>ability to interact selectively with biological targets <\/strong>such as proteins or receptors &#8211; one of the most persistent challenges <strong>is the inability to target the vast majority of proteins implicated in serious diseases<\/strong>. Nearly all currently available drugs rely on a single mechanism of action: inhibiting the activity of the pathological protein. Yet this approach is applicable to only a very small subset of the human proteome. Well\u2011established estimates suggest that fewer than 10\u202f% of proteins can be targeted using conventional small\u2011molecule inhibitors. The remaining 90\u202f% &#8211; often referred to as <em>undruggable<\/em> &#8211; includes key therapeutic targets across oncology, neurodegeneration, and chronic inflammatory conditions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">An emerging technology offers a potential solution: <strong>glue degraders<\/strong> &#8211; a class of small molecules capable of <strong>inducing the selective degradation of target proteins<\/strong> by leveraging the cell\u2019s intrinsic protein\u2011disposal machinery. Unlike <strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35671157\/\" target=\"_blank\" rel=\"noreferrer noopener\">PROTACs (Proteolysis\u2011Targeting Chimeras)<\/a><\/strong>, which rely on bifunctional molecules, glue degraders act as allosteric modulators. They enhance <strong>the interaction between a target protein and an E3 ubiquitin ligase<\/strong>, thereby enabling the protein to be tagged with ubiquitin and subsequently degraded by the proteasome. Crucially, this does not require simultaneous direct binding to both components.<br><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This mechanism <strong>sidesteps the need for accessible active sites on the target protein<\/strong>, meaning it could potentially target proteins that lack cavities or structural features amenable to classical drug binding. Moreover, the action of glue degraders is <strong>catalytic:<\/strong> a single molecule can trigger the degradation of multiple copies of the target protein, with significant implications for dosing and safety profiles.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"443\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"Glue degraders are small molecules that bring a target protein into proximity of a ligase protein, leading to the degradation of the target protein via the natural protein recycling machinery present in every cell.\" class=\"wp-image-18251 lazyload\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" data-src=\"https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/proxygen-glue-degraders-1024x443.jpg\" data-srcset=\"https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/proxygen-glue-degraders-1024x443.jpg 1024w, https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/proxygen-glue-degraders-300x130.jpg 300w, https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/proxygen-glue-degraders-768x332.jpg 768w, https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/proxygen-glue-degraders.jpg 1476w\"><figcaption class=\"wp-element-caption\"><em>Glue degraders are small molecules that bring a target protein into proximity of a ligase protein, leading to the degradation of the target protein via the natural protein recycling machinery present in every cell<\/em><\/figcaption><\/figure>\n<\/div>\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-glue-degraders-selective-power-and-broad-target-reach\">Glue Degraders: Selective Power and Broad Target Reach<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Glue degraders are distinguished by several key advantages:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>the <strong>expansion of the druggable proteome<\/strong> to potentially encompass nearly 100\u202f%;<\/li>\n\n\n\n<li><strong>high selectivity<\/strong>, even among highly conserved protein families;<\/li>\n\n\n\n<li><strong>complete elimination of the target protein<\/strong>, yielding a more sustained effect than mere inhibition;<\/li>\n\n\n\n<li>a <strong>recyclable mode of action,<\/strong> enabling lower doses without compromising therapeutic efficacy.<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">The first molecules of this class to enter clinical use were <strong>thalidomide derivatives<\/strong> &#8211; lenalidomide and pomalidomide &#8211; which alter the substrate specificity of the E3 ligase cereblon, promoting the degradation of transcription factors involved in haematological malignancies. In recent years, however, the field has expanded significantly, fuelled by advances in screening technologies and the combined application of omics data, structural biology, and artificial intelligence.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-proxygen-s-contribution\">Proxygen\u2019s Contribution<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">It is within this evolving landscape that <a href=\"https:\/\/proxygen.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Proxygen<\/a> has emerged. Founded in 2020 as a spin\u2011off from <a href=\"https:\/\/cemm.at\/\" target=\"_blank\" rel=\"noreferrer noopener\">CeMM, the Research Center for Molecular Medicine<\/a> in Vienna &#8211; one of Europe\u2019s leading institutes for translational biomedical research and affiliated with the Austrian Academy of Sciences &#8211; the company has developed a proprietary platform for the systematic identification of glue degraders. This platform integrates molecular screening, cellular biology, and computational approaches, enabling the discovery of novel degraders with therapeutic potential.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignleft size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"307\" height=\"377\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" alt=\"Bernd Boidol, CEO at Proxygen\" class=\"wp-image-18249 lazyload\" sizes=\"auto, (max-width: 307px) 100vw, 307px\" data-src=\"https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/proxygen-bernd-boidol.jpg\" data-srcset=\"https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/proxygen-bernd-boidol.jpg 307w, https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/proxygen-bernd-boidol-244x300.jpg 244w\"><figcaption class=\"wp-element-caption\">Bernd Boidol, CEO at Proxygen<\/figcaption><\/figure>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\">As Bernd Boidol, CEO and co\u2011founder of Proxygen, explains:<br>\u00ab<em>Our platform was born out of the need to overcome the limitations of the serendipitous approach traditionally used in the discovery of glue degraders. We\u2019ve managed to bring structure and rationale to what has historically been an inefficient process, drawing on expertise developed within the academic research setting<\/em>\u00bb.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Today, the company has a team of 35 people and is approximately one year away from entering clinical trials with its first molecular candidate. This compound is designed to degrade a protein that, until now, has been considered entirely untreatable &#8211; a protein implicated in various cancers, including breast and gastric carcinomas. \u00ab<em>There were no active inhibitors available for this protein<\/em>\u00bb, Boidol emphasises, \u00ab<em>and that\u2019s precisely why we believe targeted degradation could mark a therapeutic breakthrough for many patients<\/em>\u00bb.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-outlook-and-future-applications\">Outlook and Future Applications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Beyond its first clinical candidate, Proxygen has already identified several other promising glue degraders and aims to significantly expand its pipeline to include a wide array of additional targets. Scaling up the platform remains a key strategic priority, and to that end, the company is actively exploring partnerships with major pharmaceutical firms and institutional investors.<br>\u00ab<em>We are already collaborating with some of the world\u2019s leading pharmaceutical companies. Partnerships are essential for scaling, but they must be built on solid scientific foundations and a genuine sharing of expertise<\/em>\u00bb, Boidol states.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company adopts a focused, <a href=\"https:\/\/tech4future.info\/deep-learning-molecole-3d-farmaci\/\" target=\"_blank\" rel=\"noreferrer noopener\">pragmatic approach to molecular modelling<\/a> and <a href=\"https:\/\/tech4future.info\/en\/data-driven-materials-generative-ai\/\" target=\"_blank\" rel=\"noreferrer noopener\">artificial intelligence<\/a>, steering clear of sweeping claims. \u00ab<em>We\u2019re not an AI company<\/em>\u00bb, says Boidol, \u00ab<em>but we harness AI where it adds value &#8211; for instance, in structural analysis and predicting protein\u2013protein interactions. That said, what\u2019s observed in silico must always be validated in vitro and in cellulo. The feedback loop between modelling and empirical data is essential<\/em>\u00bb.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-paradigm-shift-for-the-entire-sector\">A Paradigm Shift for the Entire Sector<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The rising interest in glue degraders is reflected not only in a growing body of recent publications but also in the increasing attention from biotech investors. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25999370\/\" target=\"_blank\" rel=\"noreferrer noopener\">A landmark study by Winter et\u202fal., published in <em>Cell<\/em> in 2015<\/a>, demonstrated the ability of these molecules to target previously unreachable proteins <em>in vivo<\/em>, paving the way for large\u2011scale preclinical validation. The potential is such that glue degraders are now seen <strong>as a possible future mainstay of pharmacological strategy<\/strong> &#8211; alongside small molecules, monoclonal antibodies, and RNA\u2011based therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The direction of travel is clear: to make previously untreatable pathological targets therapeutically accessible and to broaden the scope of treatable diseases &#8211; not through incremental improvements, but by ushering in a <strong>genuine technological leap<\/strong>. As Boidol puts it: \u00ab<em>Our goal is easy to state, but far harder to achieve: to turn a lab\u2011based technology into real\u2011world therapies. A good idea is not enough &#8211; it takes time, rigour, and an ecosystem capable of supporting the entire development journey<\/em>\u00bb.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-glimpses-of-futures\">Glimpses of Futures<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">To better understand the future trajectories of glue degraders, we can apply the <strong>STEPS framework<\/strong>, which assesses the potential impact of emerging technologies across five interconnected dimensions: Social, Technological, Economic, Political, and Sustainability.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>S \u2013 SOCIAL<\/strong><br>Improved access to more effective treatments for serious, currently untreatable diseases could radically reshape the patient experience and shift societal perceptions of illnesses long considered incurable. The ability to intervene earlier and with greater precision may lighten the caregiving burden on families and healthcare systems, ultimately prompting a redefinition of care pathways.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>T \u2013 TECHNOLOGICAL<\/strong><br>Glue degrader platforms represent a new therapeutic modality &#8211; catalytic and selective &#8211; with the potential to <a href=\"https:\/\/tech4future.info\/en\/proteomics-pharmacology-precision-medicine\/\" target=\"_blank\" rel=\"noreferrer noopener\">significantly expand the boundaries of molecular pharmacology<\/a>. Their integration with structural biology, high\u2011throughput screening, and structured AI systems is likely to accelerate the discovery of new candidates and enhance the personalisation of treatment in the coming years.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E \u2013 ECONOMIC<\/strong><br>The economic and industrial implications are substantial. Should glue degraders achieve clinical validation, they may give rise to new therapeutic markets, while also reducing costs associated with ineffective treatments and lifelong disease management. Companies capable of developing scalable platforms will enjoy a strong competitive advantage in the biotech and pharmaceutical sectors.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>P \u2013 POLITICAL<\/strong><br>Political and regulatory challenges will focus primarily on establishing new standards for the approval and validation of protein\u2011degradation\u2011based drugs. Regulatory harmonisation across agencies will be essential to facilitate market access for these novel compounds &#8211; without compromising safety or efficacy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>S \u2013 SUSTAINABILITY<\/strong><br>From an environmental standpoint, the use of lower doses and more targeted mechanisms of action could reduce pharmaceutical waste and the ecological toxicity burden. Furthermore, enhanced therapeutic efficacy could lead to shorter treatment cycles and more efficient use of healthcare resources, indirectly supporting the long\u2011term sustainability of health systems.<\/p>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-uagb-info-box uagb-block-0ca11306 uagb-infobox__content-wrap  uagb-infobox-icon-above-title uagb-infobox-image-valign-top\"><div class=\"uagb-ifb-content\"><div class=\"uagb-ifb-icon-wrap\"><svg xmlns=\"https:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 512 512\"><path d=\"M0 256C0 114.6 114.6 0 256 0C397.4 0 512 114.6 512 256C512 397.4 397.4 512 256 512C114.6 512 0 397.4 0 256zM371.8 211.8C382.7 200.9 382.7 183.1 371.8 172.2C360.9 161.3 343.1 161.3 332.2 172.2L224 280.4L179.8 236.2C168.9 225.3 151.1 225.3 140.2 236.2C129.3 247.1 129.3 264.9 140.2 275.8L204.2 339.8C215.1 350.7 232.9 350.7 243.8 339.8L371.8 211.8z\"><\/path><\/svg><\/div><div class=\"uagb-ifb-title-wrap\"><h4 class=\"uagb-ifb-title\">NOTE<\/h4><\/div><p class=\"uagb-ifb-desc\"><em>The interview with Bernd Boidol, CEO of Proxygen, was conducted during ViennaUP\u202f2025, Austria\u2019s premier festival dedicated to innovation and the startup ecosystem. One of the event\u2019s key highlights, <strong>Connect Day<\/strong>, brought together public institutions, venture capital firms, research\u2011promotion agencies, and innovative companies &#8211; all with the aim of strengthening Austria\u2019s position as a European hub for emerging\u2011tech entrepreneurship.<br>This initiative aligns closely with the strategy of the Austrian federal government, which supports innovation not only through fiscal measures such as the 14\u202f% R&amp;D tax credit &#8211; but also through a coordinated ecosystem of public support structures. These include entities such as <a href=\"https:\/\/aba.gv.at\/en\/\" target=\"_blank\" rel=\"noreferrer noopener\">ABA &#8211; Austrian Business Agency<\/a>, <a href=\"https:\/\/www.aws.at\/en\/about-us\/ueber-die-aws\/\" target=\"_blank\" rel=\"noreferrer noopener\">AWS<\/a>, and <a href=\"https:\/\/www.ffg.at\/en\" target=\"_blank\" rel=\"noreferrer noopener\">FFG<\/a>, all of which are active in facilitating investment, international collaboration, and industrial development. Since 2020, ABA has supported over 180 international startups and scale\u2011ups in establishing a presence in Austria, contributing to the creation of more than 1,100 highly skilled jobs. Proxygen\u2019s work in the field of glue degraders stands as a prime example of how advanced research, public infrastructure, and venture capital can converge to foster a thriving deep\u2011tech ecosystem.<\/em><\/p><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":36,"featured_media":18254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1096],"tags":[],"class_list":["post-18270","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science"],"acf":[],"modified_by":"Nicoletta Boldrini","uagb_featured_image_src":{"full":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future.jpg",1312,736,false],"thumbnail":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-150x150.jpg",150,150,true],"medium":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-300x168.jpg",300,168,true],"medium_large":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-768x431.jpg",768,431,true],"large":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-1024x574.jpg",1024,574,true],"1536x1536":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future.jpg",1312,736,false],"2048x2048":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future.jpg",1312,736,false],"inner-slider":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-1116x652.jpg",1116,652,true],"featured-blog":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-543x357.jpg",543,357,true],"large-blog":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-524x276.jpg",524,276,true],"medium-blog":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-415x276.jpg",415,276,true],"related-large":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-343x248.jpg",343,248,true],"related-small":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-343x198.jpg",343,198,true],"normal-blog":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-306x198.jpg",306,198,true],"small-blog":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-95x96.jpg",95,96,true],"small-author":["https:\/\/tech4future.info\/wp-content\/uploads\/2025\/06\/glue-degraders-graphic-concept-Cover-Tech4Future-70x70.jpg",70,70,true]},"uagb_author_info":{"display_name":"Maria Teresa Della Mura","author_link":"https:\/\/tech4future.info\/en\/author\/miti-della-mura\/"},"uagb_comment_info":0,"uagb_excerpt":null,"meta_box":{"standard":[{"title":"Druggability and \u201cUndruggable\u201d Proteins: A Defining Challenge in Modern Pharmacology","link":"#h-druggability-and-undruggable-proteins-a-defining-challenge-in-modern-pharmacology"},{"title":"Glue Degraders: Selective Power and Broad Target Reach","link":"#h-glue-degraders-selective-power-and-broad-target-reach"},{"title":"Proxygen\u2019s Contribution","link":"#h-proxygen-s-contribution"},{"title":"Outlook and Future Applications","link":"#h-outlook-and-future-applications"},{"title":"A Paradigm Shift for the Entire Sector","link":"#h-a-paradigm-shift-for-the-entire-sector"},{"title":"Glimpses of Futures","link":"#h-glimpses-of-futures"}],"content":false,"name":false,"role":false,"type":false,"category":false,"count":false,"btn":false,"link":false,"layout":false,"title":false,"director":false,"user":false,"email":false,"posts":false,"description":false,"form":false,"subtitle":false,"innertitle":false,"background":false},"_links":{"self":[{"href":"https:\/\/tech4future.info\/en\/wp-json\/wp\/v2\/posts\/18270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tech4future.info\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tech4future.info\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tech4future.info\/en\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/tech4future.info\/en\/wp-json\/wp\/v2\/comments?post=18270"}],"version-history":[{"count":0,"href":"https:\/\/tech4future.info\/en\/wp-json\/wp\/v2\/posts\/18270\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tech4future.info\/en\/wp-json\/wp\/v2\/media\/18254"}],"wp:attachment":[{"href":"https:\/\/tech4future.info\/en\/wp-json\/wp\/v2\/media?parent=18270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tech4future.info\/en\/wp-json\/wp\/v2\/categories?post=18270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tech4future.info\/en\/wp-json\/wp\/v2\/tags?post=18270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}